FLT3 mutations in childhood acute lymphoblastic leukemia

被引:171
作者
Armstrong, SA
Mabon, ME
Silverman, LB
Li, AH
Gribben, JG
Fox, EA
Sallan, SE
Korsmeyer, SJ
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA
[4] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA
[5] Howard Hughes Med Inst, Boston, MA 02115 USA
关键词
D O I
10.1182/blood-2003-07-2441
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Activating mutations of the FLT3 receptor tyrosine kinase are common in acute myelogenous leukemia (AML) but are rare in adult acute lymphoblastic leukemia (ALL). We have recently shown that FLT3 is highly expressed and often mutated in ALLs with rearrangement of the mixed lineage leukemia (MLL) gene on chromosome 11q23. Because hyperdiploid ALL samples also show high-level expression of FLT3, we searched for the presence of FLT3 mutations in leukemic blasts from 71 patients with ALL. The data show that approximately 25% (6 of 25) of hyperdiploid ALL samples possess FLT3 mutations, whereas only 1 of 29 TEL/AML1-rearranged samples harbored mutations (P = .04, Fisher exact test). Three mutations are novel in-frame deletions within a 7-amino acid region of the receptor juxtamembrane domain. Finally, 3 samples from patients whose disease would relapse harbored FLT3 mutations. These data suggest that patients with hyperdiplold or relapsed ALL might be considered candidates for therapy with newly described small-molecule FLT3 inhibitors. (C) 2004 by The American Society of Hematology.
引用
收藏
页码:3544 / 3546
页数:3
相关论文
共 20 条
[1]   Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification [J].
Armstrong, SA ;
Kung, AL ;
Mabon, ME ;
Silverman, LB ;
Stam, RW ;
Den Boer, ML ;
Pieters, R ;
Kersey, JH ;
Sallan, SE ;
Fletcher, JA ;
Golub, TR ;
Griffin, JD ;
Korsmeyer, SJ .
CANCER CELL, 2003, 3 (02) :173-183
[2]   MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia [J].
Armstrong, SA ;
Staunton, JE ;
Silverman, LB ;
Pieters, R ;
de Boer, ML ;
Minden, MD ;
Sallan, SE ;
Lander, ES ;
Golub, TR ;
Korsmeyer, SJ .
NATURE GENETICS, 2002, 30 (01) :41-47
[3]   The roles of FLT3 in hematopoiesis and leukemia [J].
Gilliland, DG ;
Griffin, JD .
BLOOD, 2002, 100 (05) :1532-1542
[4]   Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors [J].
Hirota, S ;
Isozaki, K ;
Moriyama, Y ;
Hashimoto, K ;
Nishida, T ;
Ishiguro, S ;
Kawano, K ;
Hanada, M ;
Kurata, A ;
Takeda, M ;
Tunio, GM ;
Matsuzawa, Y ;
Kanakura, Y ;
Shinomura, Y ;
Kitamura, Y .
SCIENCE, 1998, 279 (5350) :577-580
[5]   CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML) [J].
Kelly, LM ;
Yu, JC ;
Boulton, CL ;
Apatira, M ;
Li, J ;
Sullivan, CM ;
Williams, I ;
Amaral, SM ;
Curley, DP ;
Duclos, N ;
Neuberg, D ;
Scarborough, RM ;
Pandey, A ;
Hollenbach, S ;
Abe, K ;
Lokker, NA ;
Gilliland, DG ;
Giese, NA .
CANCER CELL, 2002, 1 (05) :421-432
[6]   Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain [J].
Kiyoi, H ;
Ohno, R ;
Ueda, R ;
Saito, H ;
Naoe, T .
ONCOGENE, 2002, 21 (16) :2555-2563
[7]   Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia:: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors [J].
Kottaridis, PD ;
Gale, RE ;
Langabeer, SE ;
Frew, ME ;
Bowen, DT ;
Linch, DC .
BLOOD, 2002, 100 (07) :2393-2398
[8]   A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo [J].
Levis, M ;
Allebach, J ;
Tse, KF ;
Zheng, R ;
Baldwin, BR ;
Smith, BD ;
Jones-Bolin, S ;
Ruggeri, B ;
Dionne, C ;
Small, D .
BLOOD, 2002, 99 (11) :3885-3891
[9]   FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress [J].
Libura, M ;
Asnafi, V ;
Tu, A ;
Delabesse, E ;
Tigaud, I ;
Cymbalista, F ;
Bennaceur-Griscelli, A ;
Villarese, P ;
Solbu, G ;
Hagemeijer, A ;
Beldjord, K ;
Hermine, O ;
Macintyre, E .
BLOOD, 2003, 102 (06) :2198-2204
[10]   Translocation (2;8)(p12;q24) associated with a cryptic t(12;21)(p13;q22) TEL/AML1 gene rearrangement in a child with acute lymphoblastic leukemia [J].
Loh, ML ;
Samson, Y ;
Motte, E ;
Moreau, LA ;
Dalton, V ;
Waters, S ;
Sallan, SE ;
Gilliland, DG .
CANCER GENETICS AND CYTOGENETICS, 2000, 122 (02) :79-82